Orphan-Drug Designation From FDA And Positive Scientific Advice From EMA

Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, recently announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation (ODD) for ABTL0812, its PI3K/Akt/mTOR pathway inhibitor, for the treatment of the pediatric cancer neuroblastoma and that it has received positive Scientific Advice from the European Medicines Agency (EMA) for its development in the same indication.

Source: Pharmaceutical Online News - October 9, 2015 Category: Pharmaceuticals Source Type: news